PDCD1 and neoplasm: In this study, we showed that the therapeutic effects of anti-PD-1 in the CT26 model correlate with the preferential expansion of low avidity tumor-specific CD8+ T cells (Tetlo) with a precursor exhausted phenotype and high cytotoxic function.